AVR for Asymptomatic Severe AS 13 Feb 2025. JAMA Cardiology .

AVR for Asymptomatic Severe AS

13 Feb 2025. JAMA Cardiology .

Key Takeaways from the Article: Cardiologists Recommend AVR for Asymptomatic Severe AS

1. Default Treatment Recommendation:

• Experts propose that aortic valve replacement (AVR) should be the standard treatment for asymptomatic severe aortic stenosis (AS) instead of clinical surveillance (CS).

• Exceptions may apply due to anatomical or clinical factors.

2. TAVR vs. SAVR – Case-by-Case Decision:

• Both transcatheter AVR (TAVR) and surgical AVR (SAVR) can provide positive outcomes.

• The choice should be based on anatomical suitability, patient age, comorbidities, and personal preference.

3. Supporting Clinical Evidence:

• EARLY TAVR Trial:

• Included 901 patients (mean age: 75.8 years).

• TAVR significantly reduced the primary endpoint (death, stroke, or hospitalization) compared to CS (26.8% vs. 45.3%).

• AVATAR Trial:

• Included 157 low-risk patients (mean age: 67 years).

• Early SAVR led to better outcomes compared to conservative treatment (23.1% vs. 46.8% for primary endpoint).

4. Concerns About Valve Durability:

• While long-term durability of valves remains uncertain, early intervention is still recommended.

• The timing of a second procedure is likely similar, regardless of early AVR or CS strategy.

5. Addressing Public Health Concerns:

• Delayed or inadequate treatment of severe AS remains a major issue.

• Shifting to prompt AVR can improve patient outcomes and healthcare resource utilization.

6. Call to Action:

• Experts strongly advocate for a paradigm shift toward earlier AVR intervention.

• “It is time to act.”